Thousand Oaks, CA, United States of America

Mei-Mei Tsai

This inventor holds 16 USPTO granted patents and 3 published patent applications and 5 EPO patents. Top assignee: Amgen Inc.. Active years: 2006-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mei-Mei Tsai. Retrieved from https://idiyas.com/inventor/mei-mei-tsai

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 3)

% Patents Active = 87.5

EPO Patents = 5 (Patent Applications = 8)

Average Co-Inventor Count = 4.1

ph-index = 5

Forward Citations = 142(Granted Patents)

Company Filing History:

16 out of 2,072

Amgen Inc.

patents

Years Active: 2006-2021

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10981999 - Dual receptor antagonistic antigen-binding proteins and uses thereof (2021-04-20),

2. 10266598 - Dual receptor antagonistic antigen-binding proteins and uses thereof (2019-04-23),

3. 10227406 - Cannabinoid receptor-1 (CB1) monoclonal antibodies (2019-03-12),

4. 10035861 - Compositions and methods relating to anti-IGF-1 receptor antibodies (2018-07-31),

5. 9708375 - Inhibitory polypeptides specific to WNT inhibitors (2017-07-18),

6. 9688756 - Variant Fc-polypeptides with enhanced binding to the neonatal Fc receptor (2017-06-27),

7. 9453080 - Dual receptor antagonistic antigen-binding proteins and uses thereof (2016-09-27),

8. 8895008 - Compositions and methods relating to anti-IGF-1 receptor antibodies (2014-11-25),

9. 8541201 - Thrombopoietic compounds (2013-09-24),

10. 8460662 - Compositions and methods relating to anti-IGF-1 receptor antibodies (2013-06-11),

11. 8309092 - Wise binding agents and epitopes (2012-11-13),

12. 8168409 - Compositions and methods relating to anti-IGF-1 receptor antibodies (2012-05-01),

13. 8043620 - Wise binding agents and epitopes (2011-10-25),

14. 7981425 - Thrombopoietic compounds (2011-07-19),

15. 7871611 - Compositions and methods relating to anti IGF-1 receptor antibodies (2011-01-18),

Title: The Innovative Contributions of Mei-Mei Tsai

Introduction

Mei-Mei Tsai is a prominent inventor based in Thousand Oaks, California. She has made significant contributions to the field of biotechnology, particularly in the development of therapeutic proteins. With a total of 16 patents to her name, Tsai's work has the potential to impact the treatment of various pathological conditions.

Latest Patents

One of her latest patents is focused on dual receptor antagonistic antigen-binding proteins and their uses. This disclosure relates to antagonistic dual receptor antigen-binding proteins, such as antibodies, and methods for using these dual receptor antibodies in the treatment of pathological diseases. The dual receptor antibodies may include an antibody to ActRII receptors, which can be utilized to treat conditions such as muscle wasting diseases or any disease that necessitates stimulation of muscle growth.

Career Highlights

Mei-Mei Tsai is currently employed at Amgen Inc., a leading biotechnology company known for its innovative approaches to medicine. Her work at Amgen has allowed her to further her research and development efforts in the field of therapeutic proteins.

Collaborations

Throughout her career, Tsai has collaborated with notable colleagues, including Rajendra V Deshpande and Frank J Calzone. These collaborations have contributed to the advancement of her research and the successful development of her patented technologies.

Conclusion

Mei-Mei Tsai's innovative work in the field of biotechnology, particularly her advancements in dual receptor antagonistic antigen-binding proteins, showcases her dedication to improving therapeutic options for patients. Her contributions continue to pave the way for future innovations in medical treatments.

Profile summary based on public USPTO records.